Guardant Health is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer patients.
Read More
The study suggests that such liquid biopsies could help personalize treatment for oligometastatic colorectal cancer.
Read More
Growth of RNA sequencing allows physicians and researchers to analyze a patient’s full genetic profile.
Read More
FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read More
Simple blood tests to replace painful, invasive biopsies for cancer diagnosis will soon become more common after several recent FDA approvals, according to a report in USA Today.
Read More